Trial intelligence / Profile preview

Modified FOLFIRINOX with or without preoperative chemoradiotherapy for borderline resectable pancreatic cancer

2014-005681-29Phase 2Terminated

Sponsor
Institut de Cancérologie de Lorraine
Start
Jul 2015
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial of capecitabine and FOLFIRINOX in pancreatic cancer (PC) (2 arms), sponsored by Institut de Cancérologie de Lorraine. Primary endpoint: Histological R0 resection rate. Started Jul 2015; status: terminated.

02

Drugs

capecitabineFOLFIRINOX
03

Conditions

pancreatic cancer (PC)

Beyond the preview

Go deeper on 2014-005681-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-005681-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call